Reported 9 days ago
This article discusses three healthcare stocks that analysts find surprisingly underrated: Bristol Myers Squibb, Moderna, and Pfizer. Despite facing challenges, these companies have potential for growth and could be good buys for patient investors. Bristol Myers Squibb is trading at a low valuation, Moderna is developing promising new products, and Pfizer's extensive pipeline may lead to future revenue growth.
Source: YAHOO